Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

EMA’s reluctance in approving drugs for the condition underscores Europe’s prioritisation of long-term safety over rapid ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

Hi, it’s Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer’s drugs are finally becoming available but ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid that’s given as an infusion into a vein. It’s usually given once every ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...